Explore Stanford technologies available for licensing:

Technology Reference
Stanford ref. no S19-058
CZ Biohub ref. no. CZB-179S

Researchers at Stanford University have described a novel therapeutic target for Alzheimer's disease.

Stanford scientists developed a comprehensive, minimally invasive, dual-catheter pulsed field device that utilizes a rapid and simple integrated mapping/ablation strategy for the treatment of Atrial Fibrillation.

Researchers at Stanford and UCSF have discovered a strong association between serious, potentially fatal, delayed hypersensitivity reactions that occur in a subset of patients exposed to IL-1/IL-6 inhibitors and HLA-DRB1*15 alleles that are common across ancestries.

Researchers at Stanford University have discovered that the absence of a long non coding RNA (lnc122) predisposed mice to high numbers of hepatocellular carcinomas (HCC), and its replacement decreased the risk of HCC.

Stanford and Baylor researchers have discovered an exercise-induced lactate-derived metabolite that mediates the anorexigenic and anti-obesity effects of physical activity.

Discrete water sampling is resource and time intensive. It also involves the need for the scientist with or without a vessel to be on site to take the discrete sample.

Stanford Reference: Dockets S18-414 and S19-371:

Stanford researchers have developed methods for optimizing peptide vaccines, with candidate peptides against EGFPvIII-expressing glioblastoma and SARS-CoV-2.

Researchers at Stanford University have identified new CDK19-selective inhibitors for the treatment of triple negative breast cancer.

Stanford inventors have developed an information theoretic, seizure detection algorithm for electroencephalography (EEG) towards improving diagnosis, management, and treatment of patients with epilepsy.

Despite their cytotoxic capacity, neutrophils are often co-opted by cancers to promote immunosuppression, tumor growth, and metastasis. Consequently, these cells have received little attention as potential cancer immunotherapeutic agents.

Researchers at Stanford University have discovered a new type of integrin-mediated cell adhesion, called curved adhesion, that represents the dominant structure in 3D physiological environments.

Stanford inventors have developed a novel cancer detection assay that relies on sequencing single DNA molecules.

Targeted protein degradation is an emerging strategy for the elimination of classically undruggable proteins. Mucins are known to be involved in tumor-progressive pathways but are difficult to target using small molecules and antibodies.

Stanford researchers developed a system that uses an individual's genetic information to predict autoimmune/inflammatory disease risk.